Erbitux is expected to be a first-line drug against head and neck cancer
-
Last Update: 2020-07-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
, U.Sbiopharmaceutical companies ImClone and Persimmon squipbo recently released the results of Phase III clinical studies using the monoantinodrug Erbitux and chemotherapy drug ligandThe results showed that the drug program can extend the survival of patients with head and necktumorsErbitux is a ninth-based monoclonal antibody drug developed jointly by ImClone and Baxter, targeting epithelial growth factors, first launched in the United States in 2004 and is a second-line drug that combines radiotherapytumorand colorectal cancerAccording to the American Cancer Society, 81,550 patients have been diagnosed with head and necktumors, including tongue cancer, oral cancer, mumps, throat cancer, vocal cord cancer and lymphatic adenocarcinoma in the upper neck, and more than 12,900 will die this yearFaced with this huge drug market, ImClone and Persimmon are working to get Erbitux into the first-line therapeutic sourating teamThis Phase III clinical study included 400 patients with head and neck tumors, With Erbitux and chemotherapy drugs as the treatment group, and chemotherapy drugs themselves as control groups, the results showed a significant improvement in the overall survival rate of the treatment experimental groupThis result is likely to lead to the approval of the Erbitux program as a first-line treatment(Zhong Ming)(reproduced from the Medical Economics Journal)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
